Efficacy of Ki-67 antigen staining in papanicolaou (Pap) smears in post- menopausal women with atypia - An audit

Cytopathology

Volumn 10, Issue 6, 1999, Pages 369-374

  Ejersbo, Dorthe ^a   Jensen, H A ^a   Holund B ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Atrophy; Atypia; Cervical smear; Immunocytochemistry; Ki 67; MIB 1

Indexed keywords

KI 67 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; COLPOSCOPY; CYTODIAGNOSIS; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL AUDIT; PAPANICOLAOU TEST; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; ATROPHY; CARCINOMA IN SITU; CERVIX UTERI; CONDYLOMATA ACUMINATA; DENMARK; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MUCOUS MEMBRANE; POSTMENOPAUSE; QUALITY ASSURANCE, HEALTH CARE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0032785096     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2303.1999.00205.x     Document Type: Article

References (20)

1. 1 DeMay R. The Art and Science of Cytopathology, 1st edn. Chicago: ASCP Press, 1996: 116-8.
2. 2 Bibbo M, ed. Comprehensive Cytopathology, 2nd edn. New York: W. B. Saunders, Co., 1997: 207-8.
3. 3 Kurman R, Solomon D. The Bethesta System for Reporting Cervical/Vaginal Cytologic Diagnoses, 1st edn. New York: Springer-Verlag Inc., 1994: 40.
4. 4 Hudson E. The borderline cervical smear. Cytopathol 1995; 6: 135-9.
5. 5 Keebler C. The proliferation test. An aid in differential cytodiagnosis. In: Wied GL, ed. Compendium in Diagnostic Cytology, 7th edn. Chicago: ToC, 1992: 108-9.
6. 6 Bulten J, Wiente S, Poddighe P, Hanselaar A. Determination of DNA characteristics of atrophic cells of cervix uteri. (Abstr.) 23rd European Congress of Cytology 1996.
7. 7 Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathol 1990; 17: 489-503.
8. 8 Pheiffer P, Grabau DA, Nielsen O, Clausen PP. Immunohistochemical bulk staining of slides using a Rack peroxidase-labelled streptavidin-biotin technique. Appl Immounohistochem 1996; 4: 135-8.
9. 9 Teaff NL, Malone JM Jr, Ginsburg KA. Cervical dysplasia in the postmenopausal female: diagnosis and treatment. Int J Gynecol Obstet 1990; 34: 145-9.
10. 10 Weintraub NT, Violi E, Freedman M. Cervical cancer screening in women aged 65 and over. JAGS 1987; 35: 870-5.
11. 11 Mandelblatt J, Schechter C, Fahs M. Clinical implications of screening for cervical cancer under Medicare. Am J Obstet Gynecol 1991; 164: 644-51.
12. 12 Waddell CA. The influence of the cervix on smear quality. I. Atrophy. An audit of cervical smears taken post-colposcopic management of intraepithelial neoplasia. Cytopathol 1997; 8: 274-81.
13. 13 Abati A, Jaffurs W, Wilder AM. Squamous atypia in the atrophic cervical vaginal smear. A new look at an old problem. Cancer (Cancer Cytopathol) 1998; 84: 218-25.
14. 14 Koike N, Kasamatsu T. Efficacy of the Cytobrush method in aged patients. Diagn Cytopathol 1994; 10: 311-4.
15. 15 Heatley MK. What is the value of proliferation markers in the normal and neoplastic cervix? Histol Histopathol 1998; 13: 249-54.
16. 16 Boon ME, van Dunné FMF, Vardaxis NJ. Recognition of atypical reserve cell hyperplasia in cervical smears and its diagnostic significance. Mod Pathol 1995; 8: 786-94.
17. 17 van Hoeven KH, Kovatish AJ, Oliver RE. Immunocytochemical detection of squamous intraepithelial lesions in cervical smears. Mod Pathol 1996; 9: 407-12.
18. 18 Beilby JOW, Bourne R, Guillebaud J, Steele ST. Paired cervical smears: a method of reducing the false-negative rate in population screening. Obstet Gynecol 1982; 60: 46-48.
19. 19 Bartoo GT, Lee JSJ, Bartels PH, Kiviat NB, Nelson AC. Automated prescreening of conventionally prepared cervical smears: a feasibility study. Lab Invent 1992; 66: 116-22.
20. 20 Boon ME, Kleinschmidt-Guy E, Ouwerkerk-Noordam L. Papnet for analysis of proliferating (MIB-1 positive) cell populations in cervical smears. Eur J Morphol 1994; 32: 78-85.